Skip to Content

Sumit K. Subudhi, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

Research Interests

My research interests are to investigate how androgen receptor pathway signaling influences T cell activation, differentiation, and migration to tumor sites. I would like to expand on this understanding to develop rational drug combinations against prostate cancer.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St
Unit 1374
Unit Number: 1374
Houston, TX 77030-3721
Room Number: CPB7.3514

Education & Training

Degree-Granting Education

2007 The University of Chicago, Pritzker School of Medicine, Chicago, IL, MD, Medicine
2004 The University of Chicago, Division of Biological Sciences, Chicago, IL, PhD, Biological Science
1994 The University of Pennsylvania, College of Arts and Sciences, Philadelphia, PA, BA, Biological Basis of Behavior

Postgraduate Training

7/2009-6/2013 Clinical Fellowship, Medical Oncology Fellowship, Memorial Sloan-Kettering Cancer Center, New York, NY
6/2007-6/2009 Clinical Residency, Internal Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY

Board Certifications

11/2013 American Board of Internal Medicine-Medical Oncology
10/2010 American Board of Internal Medicine-Internal Medicine

Honors and Awards

2014 Young Investigator Award, Prostate Cancer Foundation
2013 Advanced Scholar, UT MD Anderson Cancer Center
2011 ASCO Poster Discussion Session, American Society of Clinical Oncology
2011 NIH Clinical Scholars Biomedical Research Training Program, National Institutes of Health
2011 NIH Loan Repayment Program, National Institutes of Health
2006 Francis L. Lederer MD/PhD Scholars Research Grant, University of Chicago
2004 Doolittle - Harrison Travel Fellowship, University of Chicago
2002 Best Poster Presentation, University of Chicago
2000 NIH Pediatric Growth and Development Training Grant, National Institutes of Health
2000 Winner of Sixth Annual Medical Student Poster Competition, American Society of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36, 2016. e-Pub 6/21/2016. PMCID: PMC4915058.
2. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7:12335, 2016. e-Pub 8/2016. PMID: 27498556.
3. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32, 3/2014. PMID: 24598590.
4. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309-22, 12/5/2013. PMID: 24315100.
5. Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res 19(22):6112-25, 11/2013. e-Pub 9/2013. PMID: 24081977.
6. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 13(11):1105-13, 11/2012. e-Pub 10/2012. PMID: 23059047.
7. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol 175(2):1295-300, 7/2005. PMID: 16002734.
8. Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 115(3):711-7, 3/2005. PMCID: PMC546456.
9. Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A 101(39):14198-203, 9/2004. e-Pub 9/2004. PMCID: PMC521136.
10. Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 113(5):694-700, 3/2004. PMCID: PMC351315.
11. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171(7):3348-52, 10/2003. PMID: 14500627.
12. Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8(12):1405-13, 12/2002. e-Pub 11/2002. PMID: 12426559.
13. Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol 168(9):4480-7, 5/2002. PMID: 11970992.
14. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168(3):1457-65, 2/2002. PMID: 11801689.
15. Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AL. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunology 167(4):1996-2003, 2001. PMID: 11489981.
16. Cassel DL, Subudhi SK, Surrey S, McKenzie SE. GATA and NF-Y participate in transcriptional regulation of FcgammaRIIA in megakaryocytic cells. Blood Cells Mol Dis 26(6):587-97, 12/2000. PMID: 11112392.

Invited Articles

1. Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer Journal. In Press. NIHMSID: NIHMS755175.
2. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43). e-Pub 2/2015. PMCID: PMC4530091.
3. Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: co-stimulation verse co-inhibition. J Mol Med (Berl) 83(3):193-202, 3/2005. e-Pub 1/2005. PMID: 15630593.
4. Sun Y, Subudhi SK, Fu YX. Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends Mol Med 9(11):483-9, 11/2003. PMID: 14604826.


1. Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology 217(6):590-2, 6/2012. e-Pub 11/2011. PMID: 22459268.
2. Subudhi SK, Callahan MK, Wolchok JD. Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park) 24(14):1288, 1294, 12/2010. PMID: 21294472.


1. Subudhi SK, Aparicio A,Troncoso P, Zhang J, Gumbs C, Wu CJ, Vence LM, Logothetis CJ, Futreal A, Allison JP, Sharma P. A Feasibility Study to Determine T Cell Responses to Neoantigens Following Treatment with Ipilimumab in Men with Metastatic Castration-Resistant Prostate Carcinoma (mCRPC). J Clin Oncology, 2016 ASCO Annual Meeting 34 (#e14506), 6/2016.
2. Odisio BC, Christensen JA, Subudhi SK, Huang S, Gupta S, Ahrar K, Sheth R, Ensor J, Aparicio A. Image guided thermal ablation of prostate cancer metastases to the liver. J Clin Oncology, 2016 ASCO Annual Meeting 34 (#e16515), 6/2016.
3. Subudhi S, Aparicio A, Gao J, Zurita-Saavedra A, Araujo JC, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. Cancer Res, AACR 2016 Annual Meeting (#1402), 4/2016.
4. Subudhi, SK, Aparicio1 A, Gao J, Zurita AJ, Araujo J, Logothetis CJ, Rao B, Vence L, Allison JP, Emerson R, Yusko E, Vignali M, Robins R, Sun J, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in metastatic non-castrate prostate cancer. Prostate Cancer Foundation (PCF) - 22nd Annual Scientific Retreat, 10/2015.
5. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo J, Logothetis CJ, Rao B, Vence L, Allison JP, Emerson R, Yusko E, Vignali M, Robins H, Sun J, Sharma P. Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer. SITC - Society of Immunotherapy, Advances in Cancer Immunotherapy, 6/2015.
6. Corn P, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol, 2015 Genitourinary Cancers Symposium 33 (#5010), 5/2015.
7. Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, Le O, Logothetis CJ, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. J Clin Oncology, 2015 ASCO Annual Meeting 33 (#TPS5075), 5/2015.
8. Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu S, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormone-naïve metastatic prostate cancer (HN-mPCa). Annals of Oncology, ESMO, European Society for Medical Oncology 25 (#1053PD), 9/2014.
9. Subudhi SK, Montalvo-Ortiz W, Scher HI, Allison JP. Dissecting the therapeutic effects of anti-CTLA-4 and ADT in murine hormone-sensitive prostate cancer. J Clin Oncology, 2013 ASCO Annual Meeting 31 (#61), 2013.
10. Subudhi SK, Heller G, Danila DC, Anand A, Lacuna KP, Samoila A, Fleisher M, Scher HI. Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer. J Clin Oncology, 2013 ASCO Annual Meeting 31 (#5083), 2013.
11. Subudhi SK, Heller G, Anand A, Danila DC, Fleisher M, Scher HI. A Six-gene Panel that Predicts Survival in Men with Castration-resistant Prostate Cancer. J Clin Oncol, 2013 Genitourinary Cancers Symposium 29 (#4539), 2011.
12. Callahan MK, Yang A, Tandon S, Xu S, Subudhi SK, Roman RA, Heine AI, pogoriler E, Kuk D, Panageas K, Yuan JD, Allison JP, Wolchok JD. Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. American Society of Clinical Oncology 29 (#2505), 2011.

Book Chapters

1. Sharma P, Subudhi S, Peggs S, Goswani S, Gao J, Quezada S, Allison JP. Cancer Medicine 9th Edition. In: Chapter 13: Cancer Immunotherapy, 9, 2015. PMCID: PMC978-1-607-950-141.
2. Subudhi SK, Scher HI, Allison JP. CTLA-4 inhibitors in castration-resistant prostate cancer. In: Targeted Therapies for Castration-Resistant Prostate Cancer. Scardino PT: London, UK, 2012.

Grant & Contract Support

Title: Targeting the Immune & Non-immune Tumor-associated Microenvironments in Prostate Cancer
Funding Source: UT MD Anderson Cancer Center - Prostate Cancer Moon Shot
Role: Co-Investigator
Duration: 9/1/2015 - 8/31/2016
Title: A Feasibility Study to Determine T-cell Responses to Neoantigens Following Treatment with Ipilimumab in Men with Metastatic Castration-Resistant Prostate Carcinoma
Funding Source: UT MD Anderson Cancer Center - Prostate Cancer Moon Shot
Role: Co-Investigator
Duration: 9/1/2014 - 8/31/2015
Title: Improving Patient Selection for Immune Checkpoint Therapy: Maximizing Benefit and Minimizing Toxicities
Funding Source: Prostate Cancer Foundation
Role: Principal Investigator
Duration: 3/1/2014 - 2/28/2017

Last updated: 9/9/2016